3-羧基-2-氟苯硼酸 | 1072952-09-0

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯硼酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-羧基-2-氟苯硼酸
• 中文别名: 3-羧基-2-氟苯基硼酸
• 英文名称: 3-borono-2-fluorobenzoic acid
• 英文别名: 3-Carboxy-2-fluorophenylboronic acid
• CAS: 1072952-09-0
• 化学式: C₇H₆BFO₄
• mdl: MFCD03095128
• 分子量: 183.932
• InChiKey: DLSFOCMCMFDBOG-UHFFFAOYSA-N

物化性质

• 沸点：
  423.0±55.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-Carboxy-2-fluorophenylboronic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P302+P352: IF ON SKIN: Wash with soap and water
P321: Specific treatment (see on this label)
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-Carboxy-2-fluorophenylboronic acid
Ingredient name:
CAS number: 1072952-09-0

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H6BFO4
Molecular weight: 183.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴吡咯-2-甲醛 、 3-羧基-2-氟苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 18.0h， 生成 2-fluoro-3-(5-formyl-1H-pyrrol-2-yl)benzoic acid
  参考文献：
  名称：

  新型 5-((Arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones 作为 HIV-1 融合体的设计、合成和生物活性靶向 gp41 的抑制剂

  摘要：

  在我们之前的分子对接分析的基础上，我们设计并合成了 5-((arylfuran/1 H -pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4- ( 12a - o ) 作为 HIV-1 进入抑制剂。化合物12a - o有效抑制实验室适应和原代 HIV-1 菌株的感染，并阻止 HIV-1 介导的细胞 - 细胞融合和 gp41 六螺旋束形成。两种高活性抑制剂12b和12m 的分子对接分析含有四唑基团，表明它们都紧贴在 HIV-1 gp41 的疏水腔中，每个都与赖氨酸 574 (K574) 具有重要的离子相互作用。相比之下，12i 的分子对接，一种含有吡咯而不是呋喃环的活性较低的化合物，表明与12b和12m 的取向完全不同，并且错过了关键的相互作用。

  DOI：

  10.1021/jm101014v

文献信息

• Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors
  作者：Jay A. Markwalder、Steven P. Seitz、Yuval Blat、Lisa Elkin、John T. Hunt、Jonathan G. Pabalan、Maria N. Jure-Kunkel、Gregory D. Vite、Kelly Covello

  DOI：10.1016/j.bmcl.2016.12.015

  日期：2017.2

  The discovery of a series of structurally-novel biaryl urea IDO inhibitors is described. Optimization of a micromolar hit through iterative cycles of synthesis and screening in an assay measuring IDO-mediated intracellular conversion of tryptophan to kynurenine led to potent inhibitors with favorable selectivity and metabolic stability profiles.

  描述了一系列结构新颖的联芳基脲IDO抑制剂的发现。通过合成和筛选的迭代循环中的微摩尔击中的优化，在测定IDO介导的色氨酸向犬尿氨酸的细胞内转化的测定中，可产生具有良好选择性和代谢稳定性的有效抑制剂。
• Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
  申请人：SANOFI

  公开号：EP2998294A1

  公开（公告）日：2016-03-23

  The present invention relates to naphthyl sulfonamide phenyl derivatives of the formula I in which R1, R2, R3, R4, R5, R6, R7, R8, R10, A, X, L, q, i and R50 are defined as indicated below. The naphthyl sulfonamide phenyl derivatives I are KEAP-1 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of naphthyl sulfonamide phenyl derivatives of the formula I as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及公式I的萘磺酰胺苯衍生物，其中R1，R2，R3，R4，R5，R6，R7，R8，R10，A，X，L，q，i和R50如下所示。萘磺酰胺苯衍生物I是KEAP-1调节剂，可用于预防和/或治疗糖尿病，肥胖症，血脂异常及相关疾病。本发明还涉及将公式I的萘磺酰胺苯衍生物用作制药活性成分的用途，以及包含它们的制药组合物。
• Highly-tumor-targeted PAD4 inhibitors with PBA modification inhibit tumors in vivo by specifically inhibiting the PAD4-H3cit-NETs pathway in neutrophils
  作者：Di Zhu、Yu Lu、Bo Hu、Yuheng Pang、Bingru Liu、Miao Zhang、Wenjing Wang、Yuji Wang

  DOI：10.1016/j.ejmech.2023.115619

  日期：2023.10
• FUSED HETEROBICYCLIC ANTIVIRAL AGENTS
  申请人：[en]ENANTA PHARMACEUTICALS, INC.

  公开号：WO2024044183A1

  公开（公告）日：2024-02-29

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.